Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics
ZACKS· 2025-02-06 23:36
文章核心观点 - 公司2024年第四季度财报表现良好,营收和每股收益同比增长且超预期,部分关键指标表现出色,股票近一个月回报率高于市场,获Zacks评级“买入” [1][3] 财务数据 - 2024年第四季度营收33.3亿美元,同比增长9.8%,超Zacks共识预期0.44% [1] - 同期每股收益3.45美元,去年同期为3.30美元,超共识预期1.47% [1] 股票表现 - 过去一个月公司股票回报率为6.7%,Zacks标准普尔500综合指数变化为2.1% [3] - 股票目前Zacks排名为2(买入),短期内可能跑赢大盘 [3] 细分业务指标 生物制药实验室服务 - 营收7.67亿美元,四位分析师平均预估为7.4752亿美元,同比变化+10.4% [4] - 调整后营业收入1.308亿美元,三位分析师平均预估为1.2315亿美元 [4] 诊断实验室 - 营收25.9亿美元,四位分析师平均预估为25.7亿美元,同比变化+10.2% [4] - 调整后营业收入3.595亿美元,三位分析师平均预估为3.8285亿美元 [4]
Agco (AGCO) Reports Q4 Earnings: What Key Metrics Have to Say
ZACKS· 2025-02-06 23:36
For the quarter ended December 2024, Agco (AGCO) reported revenue of $2.89 billion, down 24% over the same period last year. EPS came in at $1.97, compared to $3.78 in the year-ago quarter.The reported revenue represents a surprise of -8.61% over the Zacks Consensus Estimate of $3.16 billion. With the consensus EPS estimate being $1.80, the EPS surprise was +9.44%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next ...
Compared to Estimates, Rithm (RITM) Q4 Earnings: A Look at Key Metrics
ZACKS· 2025-02-06 23:36
Rithm (RITM) reported $2.1 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 196.1%. EPS of $0.60 for the same period compares to $0.51 a year ago.The reported revenue represents a surprise of +70.97% over the Zacks Consensus Estimate of $1.23 billion. With the consensus EPS estimate being $0.45, the EPS surprise was +33.33%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...
Spectrum (SPB) Reports Q1 Earnings: What Key Metrics Have to Say
ZACKS· 2025-02-06 23:36
For the quarter ended December 2024, Spectrum Brands (SPB) reported revenue of $700.2 million, up 1.2% over the same period last year. EPS came in at $1.02, compared to $0.78 in the year-ago quarter.The reported revenue represents a surprise of -0.19% over the Zacks Consensus Estimate of $701.54 million. With the consensus EPS estimate being $0.91, the EPS surprise was +12.09%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...
Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-02-06 23:36
文章核心观点 - 阿斯利康2024年第四季度财报显示营收和每股收益情况,与去年同期及华尔街预期有差异,部分关键指标表现影响公司潜在业绩和股价表现 [1][2] 财务数据 - 2024年第四季度营收148.9亿美元,同比增长23.8%,比Zacks共识预期的142.8亿美元高出4.26% [1] - 2024年第四季度每股收益1.05美元,去年同期为0.73美元,比共识预期的1.07美元低1.87% [1] 股价表现 - 过去一个月阿斯利康股价回报率为6.5%,而Zacks标准普尔500综合指数变化为2.1% [3] - 该股目前Zacks排名为3(持有),表明短期内表现可能与大盘一致 [3] 各业务板块表现 - 生物制药R&I部门Symbicort美国市场营收2.99亿美元,高于两位分析师平均预估的2.3506亿美元 [4] - 肿瘤学Truqap在成熟的其他地区市场营收400万美元,高于两位分析师平均预估的350万美元 [4] - 肿瘤学Tagrisso美国市场营收7.67亿美元,高于两位分析师平均预估的7.0965亿美元 [4] - 生物制药R&I部门Fasenra美国市场营收2.99亿美元,高于两位分析师平均预估的2.7275亿美元,同比增长8.7% [4] - 合作收入总计8.15亿美元,高于四位分析师平均预估的4.1912亿美元 [4] - 联盟收入总计7.14亿美元,高于四位分析师平均预估的6.1599亿美元,同比增长68.4% [4] - 生物制药CVRM部门Seloken/Toprol - XL全球市场营收1.4亿美元,低于三位分析师平均预估的1.4696亿美元,同比下降2.8% [4] - 肿瘤学Tagrisso全球市场营收17亿美元,高于三位分析师平均预估的16.8亿美元,同比增长20% [4] - 生物制药V&I部门Synagis全球市场营收1.01亿美元,低于三位分析师平均预估的1.0219亿美元 [4] - 生物制药R&I部门Fasenra全球市场营收4.71亿美元,高于三位分析师平均预估的4.3704亿美元 [4] - 生物制药CVRM部门Brilinta全球市场营收3.41亿美元,高于三位分析师平均预估的3.1089亿美元,同比增长3.7% [4] - 生物制药CVRM部门Farxiga全球市场营收19.3亿美元,低于三位分析师平均预估的19.6亿美元,同比增长20.4% [4]
Valvoline (VVV) Reports Q1 Earnings: What Key Metrics Have to Say
ZACKS· 2025-02-06 23:36
For the quarter ended December 2024, Valvoline (VVV) reported revenue of $414.3 million, up 11% over the same period last year. EPS came in at $0.32, compared to $0.29 in the year-ago quarter.The reported revenue represents a surprise of +4.04% over the Zacks Consensus Estimate of $398.2 million. With the consensus EPS estimate being $0.31, the EPS surprise was +3.23%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...
Tapestry (TPR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-02-06 23:36
文章核心观点 - 介绍Tapestry 2024年第四季度财报情况及关键指标表现,显示公司业绩及与预期对比情况,表明股票有较好表现 [1][3] 财务数据表现 - 2024年第四季度营收22亿美元,同比增长5.3%,每股收益2美元,去年同期为1.63美元 [1] - 营收超Zacks共识预期4.14%,预期为21.1亿美元;每股收益超预期14.94%,预期为1.74美元 [1] 关键指标作用 - 一些关键指标能更好洞察公司潜在表现,对比去年数据和分析师预期,助投资者更准确预测股价表现 [2] 股票表现 - 过去一个月Tapestry股票回报率7.1%,Zacks标准普尔500综合指数变化为2.1% [3] - 股票目前Zacks排名为2(买入),短期内可能跑赢大盘 [3] 各品牌销售及运营情况 蔻驰(Coach) - 净销售额17.1亿美元,四个分析师平均预期15.8亿美元,同比增长10.9% [4] - 营业收入6.209亿美元,三个分析师平均预期5.5102亿美元 [4] 思缇韦曼(Stuart Weitzman) - 净销售额6970万美元,四个分析师平均预期8206万美元,同比下降15.2% [4] - 营业收入亏损100万美元,三个分析师平均预期盈利86万美元 [4] 凯特·丝蓓(Kate Spade) - 净销售额4.164亿美元,四个分析师平均预期4.437亿美元,同比下降9.6% [4] - 营业收入6800万美元,三个分析师平均预期6917万美元 [4]
ITT (ITT) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2025-02-06 23:36
For the quarter ended December 2024, ITT (ITT) reported revenue of $929 million, up 12.1% over the same period last year. EPS came in at $1.50, compared to $1.34 in the year-ago quarter.The reported revenue represents a surprise of +0.23% over the Zacks Consensus Estimate of $926.84 million. With the consensus EPS estimate being $1.47, the EPS surprise was +2.04%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectatio ...
Honeywell International (HON) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-02-06 23:36
For the quarter ended December 2024, Honeywell International Inc. (HON) reported revenue of $10.09 billion, up 6.9% over the same period last year. EPS came in at $2.47, compared to $2.60 in the year-ago quarter.The reported revenue represents a surprise of +2.30% over the Zacks Consensus Estimate of $9.86 billion. With the consensus EPS estimate being $2.31, the EPS surprise was +6.93%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...
Equifax (EFX) Reports Q4 Earnings: What Key Metrics Have to Say
ZACKS· 2025-02-06 23:36
文章核心观点 - 分析Equifax公司2024年第四季度财报及关键指标,评估其财务健康状况和股价表现 [1][2][3] 财务数据 - 2024年第四季度营收14.2亿美元,同比增长7%,低于Zacks共识预期1.44亿美元,差异为-1.46% [1] - 同期每股收益2.12美元,去年同期为1.81美元,高于共识预期2.10美元,差异为+0.95% [1] 股价表现 - 过去一个月Equifax股价回报率为+8.9%,而Zacks标准普尔500综合指数变化为+2.1% [3] - 股票目前Zacks排名为4(卖出),表明近期可能跑输大盘 [3] 各地区及业务板块营收情况 亚太地区 - 运营收入8400万美元,13位分析师平均预期为8645万美元,同比变化+2.2% [4] 拉丁美洲 - 运营收入9990万美元,13位分析师平均预期为1.0799亿美元,同比变化+1.3% [4] 欧洲 - 运营收入9980万美元,13位分析师平均预期为9985万美元,同比变化+6.6% [4] 加拿大 - 运营收入6510万美元,13位分析师平均预期为6484万美元,同比变化+0.3% [4] 美国信息解决方案 - 运营收入4.725亿美元,14位分析师平均预期为4.7265亿美元,同比变化+10.5% [4] 劳动力解决方案 - 运营收入5.981亿美元,14位分析师平均预期为6.1184亿美元,同比变化+6.9% [4] 国际业务总计 - 运营收入3.488亿美元,14位分析师平均预期为3.5885亿美元,同比变化+2.8% [4] 美国信息解决方案-抵押解决方案 - 运营收入3290万美元,13位分析师平均预期为3193万美元,同比变化+43.7% [4] 美国信息解决方案-金融营销服务 - 运营收入7750万美元,13位分析师平均预期为8004万美元,同比变化+0.3% [4] 劳动力解决方案-验证服务 - 运营收入5.047亿美元,13位分析师平均预期为5.1501亿美元,同比变化+10.4% [4] 美国信息解决方案-在线信息解决方案 - 运营收入3.621亿美元,13位分析师平均预期为3.611亿美元,同比变化+10.6% [4] 劳动力解决方案-雇主服务 - 运营收入9340万美元,13位分析师平均预期为9708万美元,同比变化-8.8% [4]